Glaukos (GKOS) traded lower Monday, May 4, 2026, down roughly 3% to about $136, after the company filed a Form 8-K that furnishes an investor presentation it plans to use in discussions with investors and other stakeholders. The filing itself does not indicate a new financial restatement or a discrete negative surprise, but it put fresh materials in the market and coincided with a pullback after a strong post-earnings run.

The decline looks consistent with post-earnings digestion: GKOS had rallied sharply after its late-April results and upbeat 2026 outlook, leaving the stock more vulnerable to profit-taking on days without a clear incremental catalyst. With sentiment elevated and the shares near recent highs, even a routine corporate update can act as a trigger for traders to lock in gains, particularly in higher-multiple med-tech names that have moved quickly.

Key swing factors for the next leg include any changes in management’s framing of 2026 revenue drivers inside the investor deck, updates on commercialization cadence for Epioxa, and continued execution in iDose TR. Traders will also watch whether the stock stabilizes after the early-week reset or if follow-on selling emerges as investors reassess the pace of revenue acceleration implied by the raised 2026 range.